Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OMT-28
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
OMEICOS Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
Details : OMT-28 is a first-in-class PPARα agonist small molecule drug candidate, which is currently being evaluated for the treatment of primary mitochondrial disease.
Brand Name : OMT-28
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 26, 2024
Lead Product(s) : OMT-28
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
